ClinicalTrials.gg
CompletedNCT04087720Updated Jun 26, 2024Results posted

Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant

A Phase 4 interventional study of Pegloticase in Uncontrolled Gout and Kidney Transplant, sponsored by Amgen. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-26.

Sponsored by Amgen · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing pegloticase in Gout — 1 open to participants now, 1 under way, 1 of them phase 3. Pegloticase · Gout.

Enrollment
11th of 14
20 · median 93
Started
2019
with 1 other
Phase 4
7 of 14
none open now
Registered
9th of 14
by date
Lead sponsor
8 of 14
Amgen

Among the 14 studies testing pegloticase in Gout, this one is the 11th largest by enrollment, is one of 2 that started in 2019, is one of 7 in phase 4, and was the 9th registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

1 of the 14 studies testing pegloticase in Gout is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About pegloticase

Pegloticase: first FDA approval 2010 (KRYSTEXXA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing pegloticase in Gout, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the effect of pegloticase on the response rate of sustained serum uric acid (sUA) reduction to sUA \< 6 mg/dL during Month 6 of treatment.

Read the detailed description

The study design includes: 1) a Screening Period, lasting up to 35 days; 2) a 24-week treatment period which includes an End-of-Study (Week 24) /Early Termination Visit; 3) a safety follow-up phone/email Visit 30 days after the last infusion; and 4) a 3 month post-treatment follow up visit.

Study acquired from Horizon in 2024.

03

Conditions studied

  • Uncontrolled Gout
  • Kidney Transplant

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to give ;
  • Willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the study;
  • Adult men or women ≥ 18 years of age;
  • Is a recipient of a de novo kidney from a living or deceased donor and is >1 year post transplant prior to screening;
  • Is on a stable standard of care therapy for at least 3 months prior to screening;
  • Kidney allograft is functional at entry, based on an estimated (eGFR) ≥ 15 mL/min/1.73m²;
  • Women of have a negative screening serum pregnancy test and will be required to use a medically approved form of during their participation in the study;
  • Uncontrolled gout, defined as:

    1. Hyperuricemia during screening as documented by sUA ≥ 7 mg/dL during Screening and prior to entry into the Treatment Period (Note: the sUA may be repeated up to 3 times during the Screening Period to confirm eligibility), and
    2. Inability to maintain sUA \<6 mg/dL on other urate-lowering therapy or intolerable side effects or with conventional urate-lowering therapy, and
    3. At least 1 of the following:

    i. Evidence of tophaceous deposits; ii. Recurrent gout flares defined as 2 or more flares in the 12 months prior to Screening; iii. Presence of chronic gouty arthritis;

  • Able to tolerate low-dose prednisone (\< 10 mg/day) as part of the required standard gout flare prophylaxis regimen for ≥ 1 week before the first infusion.

Exclusion criteria

Exclusion Criteria:

  • Any other organ transplant beside kidney;
  • Any severe infection, unless treated and completely resolved at least 2 weeks prior to Day 1;
  • Chronic or active virus infection;
  • Known history of virus ribonucleic acid (RNA) positivity unless treated and viral load is negative;
  • Known history of (HIV) positivity;
  • Glucose-6-phosphate dehydrogenase (G6PD) deficiency (tested at the Screening Visit);
  • Decompensated congestive heart failure or hospitalization for congestive heart failure within 3 months of the Screening Visit, uncontrolled arrhythmia, treatment for acute coronary syndrome (myocardial infarction or unstable angina), or uncontrolled blood pressure (> 160/100 mm Hg) at the end of the Screening Period (Day 1 prior to infusion);
  • Pregnant, planning to become pregnant, breastfeeding, planning to impregnate female partner, or not using an effective form of , as determined by the Investigator;
  • Prior treatment with pegloticase, another recombinant uricase (rasburicase), or concomitant therapy with a polyethylene glycol-conjugated drug;
  • Known allergy to pegylated products or history of anaphylactic reaction to a recombinant protein or porcine product;
  • Receipt of an drug within 4 weeks or 5 half-lives, whichever is longer, prior to Day 1, or plans to take an investigational drug during the study;
  • Currently receiving systemic or radiologic treatment for ongoing cancer;
  • History of within 5 years other than non-melanoma skin cancer, in situ carcinoma of cervix, early stage renal cell cancer or early stage prostate cancer that has been completely resected > 2 years prior to screening;
  • Uncontrolled hyperglycemia with a plasma glucose value > 240 mg/dL at Screening that is not subsequently controlled by the end of the Screening Period;
  • Diagnosis of osteomyelitis;
  • Known history of hypoxanthine-guanine phosphoribosyl-transferase deficiency, such as Lesch-Nyhan and Kelley-Seegmiller syndrome;
  • Unsuitable candidate for the study, based on the opinion of the Investigator (e.g., cognitive impairment), such that participation might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements or complete the study;
  • Currently receiving allopurinol, febuxostat or other urate lowering medications and unable to discontinue medication 7 days prior to Day 1; or
  • Currently receiving probenecid and unable to discontinue medication within 3 days, prior to Day 1.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Pegloticase

    Participants receive 8 mg pegloticase every 2 weeks from Day 1 through Week 22

    Biological: Pegloticase

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Serum Uric Acid (sUA) < 6 mg/dL Responders During Month 6

    sUA \< 6 mg/dL responders are defined as participants achieving and maintaining sUA \< 6 mg/dL for at least 80% of the time during Month 6, which includes pre-infusion and post-infusion results at Week 20, results at Week 21, pre-infusion and post-infusion results at Week 22, results at Week 23, results at Week 24, and unscheduled assessments of sUA collected between Week 20 and Week 24. Two-sided Exact Clopper-Pearson confidence interval is used for the calculation of the 95% confidence interval.

    Time frame: Month 6 (Weeks 20, 21, 22, 23, 24)

Secondary outcomes

  1. Percentage of sUA < 5 mg/dL Responders During Month 6

    sUA \< 5 mg/dL responders are defined as participants achieving and maintaining sUA \<5 mg/dL for at least 80% of the time during Month 6, which includes pre-infusion and post-infusion results at Week 20, results at Week 21, pre-infusion and post-infusion results at Week 22, results at Week 23, results at Week 24, and unscheduled assessments of sUA collected between Week 20 and Week 24. Two-sided Exact Clopper-Pearson confidence interval is used for the calculation of the 95% confidence interval.

    Time frame: Month 6 (Weeks 20, 21, 22, 23, and 24)

  2. Change From Baseline in Health Assessment Questionnaire (HAQ) Pain Visual Analog Scale (VAS) Score Through Week 24

    The HAQ-Pain score consists of a doubly anchored, horizontal VAS 15 cm in length, and rates a participant's pain over the past week from 0 to 100 with 0 = no pain and 100 = severe pain. Baseline is defined as the last measurement taken prior to the first infusion of pegloticase. The 95% confidence interval is a two-sided normal theory-based 95% confidence interval.

    Time frame: Baseline, Weeks 6, 14, 20, 24

  3. Change From Baseline in Heath Assessment Questionnaire - Disability Index (HAQ-DI) Score Through Week 24

    The HAQ-DI is a self-reported assessment of how a participant's illness affects their ability to function in their daily life over the past week. The HAQ-DI for a participant is calculated as the mean of the following 8 category scores: Dressing and Grooming, Arising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The HAQ-DI ranges from 0 to 3 with higher values indicating higher disability. Baseline is defined as the last measurement taken prior to the first infusion of pegloticase. The 95% confidence interval is a two-sided normal theory-based 95% confidence interval.

    Time frame: Baseline, Weeks 6, 14, 20, 24

07

Results

Posted Jul 26, 2022

Participant flow

Participant flow — Overall Study
MilestonePegloticase
Started20
Completed15
Not completed5
Withdrew: Withdrawal by subject2
Withdrew: Withdrawal by subject - covid-19 concerns3

Outcome measures

PrimaryPercentage of Serum Uric Acid (sUA) < 6 mg/dL Responders During Month 6

sUA \< 6 mg/dL responders are defined as participants achieving and maintaining sUA \< 6 mg/dL for at least 80% of the time during Month 6, which includes pre-infusion and post-infusion results at Week 20, results at Week 21, pre-infusion and post-infusion results at Week 22, results at Week 23, results at Week 24, and unscheduled assessments of sUA collected between Week 20 and Week 24. Two-sided Exact Clopper-Pearson confidence interval is used for the calculation of the 95% confidence interval.

Time frame:
Month 6 (Weeks 20, 21, 22, 23, 24)
Reported as:
Number · percentage of participants
Percentage of Serum Uric Acid (sUA) < 6 mg/dL Responders During Month 6
percentage of participantsPegloticase
Percentage of Serum Uric Acid (sUA) < 6 mg/dL Responders During Month 688.9 (65.3 to 98.6)
SecondaryPercentage of sUA < 5 mg/dL Responders During Month 6

sUA \< 5 mg/dL responders are defined as participants achieving and maintaining sUA \<5 mg/dL for at least 80% of the time during Month 6, which includes pre-infusion and post-infusion results at Week 20, results at Week 21, pre-infusion and post-infusion results at Week 22, results at Week 23, results at Week 24, and unscheduled assessments of sUA collected between Week 20 and Week 24. Two-sided Exact Clopper-Pearson confidence interval is used for the calculation of the 95% confidence interval.

Time frame:
Month 6 (Weeks 20, 21, 22, 23, and 24)
Reported as:
Number · percentage of participants
Percentage of sUA < 5 mg/dL Responders During Month 6
percentage of participantsPegloticase
Percentage of sUA < 5 mg/dL Responders During Month 688.9 (65.3 to 98.6)
SecondaryChange From Baseline in Health Assessment Questionnaire (HAQ) Pain Visual Analog Scale (VAS) Score Through Week 24

The HAQ-Pain score consists of a doubly anchored, horizontal VAS 15 cm in length, and rates a participant's pain over the past week from 0 to 100 with 0 = no pain and 100 = severe pain. Baseline is defined as the last measurement taken prior to the first infusion of pegloticase. The 95% confidence interval is a two-sided normal theory-based 95% confidence interval.

Time frame:
Baseline, Weeks 6, 14, 20, 24
Reported as:
Mean · score on a scale
Change From Baseline in Health Assessment Questionnaire (HAQ) Pain Visual Analog Scale (VAS) Score Through Week 24
score on a scalePegloticase
Change at Week 6-16.11 ± 29.230
Change at Week 14-34.81 ± 24.025
Change at Week 20-34.63 ± 27.543
Change at Week 24-33.05 ± 31.590
SecondaryChange From Baseline in Heath Assessment Questionnaire - Disability Index (HAQ-DI) Score Through Week 24

The HAQ-DI is a self-reported assessment of how a participant's illness affects their ability to function in their daily life over the past week. The HAQ-DI for a participant is calculated as the mean of the following 8 category scores: Dressing and Grooming, Arising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The HAQ-DI ranges from 0 to 3 with higher values indicating higher disability. Baseline is defined as the last measurement taken prior to the first infusion of pegloticase. The 95% confidence interval is a two-sided normal theory-based 95% confidence interval.

Time frame:
Baseline, Weeks 6, 14, 20, 24
Reported as:
Mean · score on a scale
Change From Baseline in Heath Assessment Questionnaire - Disability Index (HAQ-DI) Score Through Week 24
score on a scalePegloticase
Change at Week 6-0.30 ± 0.522
Change at Week 14-0.52 ± 0.616
Change at Week 20-0.38 ± 0.523
Change at Week 24-0.25 ± 0.611

Adverse events

Collected over From the date of first dose of treatment through 30 days after the last dose of treatment (up to Week 22 plus 30 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pegloticase0/20 (0%)5/20 (25%)16/20 (80%)
Most frequent serious events
Most frequent serious events
EventPegloticase
Atrial fibrillationCardiac disorders1/20
Duodenal ulcerGastrointestinal disorders1/20
Enterocolonic fistulaGastrointestinal disorders1/20
CellulitisInfections and infestations1/20
DiverticulitisInfections and infestations1/20
Localised infectionInfections and infestations1/20
Post procedural haemorrhageInjury, poisoning and procedural complications1/20
Most frequent other events
Showing 10 of 37
Most frequent other events
EventPegloticase
GoutMetabolism and nutrition disorders9/20
Conjunctival haemorrhageEye disorders2/20
PyrexiaGeneral disorders2/20
ArthralgiaMusculoskeletal and connective tissue disorders2/20
Nasal congestionRespiratory, thoracic and mediastinal disorders2/20
TachycardiaCardiac disorders1/20
Inner ear disorderEar and labyrinth disorders1/20
TinnitusEar and labyrinth disorders1/20
VertigoEar and labyrinth disorders1/20
Ocular hyperaemiaEye disorders1/20

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pegloticase
Mean53.9 ± 10.87
Sex: Female, Male
Sex: Female, Male(Participants)Pegloticase
Female3
Male17
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pegloticase
Hispanic or Latino3
Not Hispanic or Latino17
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pegloticase
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American7
White9
More than one race2
Unknown or Not Reported0
08

Study locations

8 sites
  • University of Alabama Birmingham
    Birmingham, Alabama 35294, United States
  • Nephrology Consultants
    Huntsville, Alabama 35805, United States
  • Keck School of Medicine of USC
    Los Angeles, California 90033, United States
  • Amicis Research Center
    Northridge, California 91324, United States
  • Genesis Clinical Research
    Tampa, Florida 33614, United States
  • Coastal Medical Research
    Brunswick, Georgia 31520, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • Clear Lake Specialties
    Webster, Texas 77598, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Jul 2021, 21 months.

Results were first posted in Jul 2022, 1 year after primary completion.

Of 19 phase 4 interventional studies under Gout, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 21 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2019
First posted
Sep 12, 2019
StartActual
Sep 9, 2019
Primary completionActual
Jul 6, 2021
CompletionActual
Sep 7, 2021
Results first posted
Jul 26, 2022
Last update
Jun 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04087720
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Sep 12, 2019
Start date
Sep 9, 2019
Primary completion
Jul 6, 2021
Completion
Sep 7, 2021
Results posted
Jul 26, 2022
Last update
Jun 26, 2024

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegloticase

Start the discussion